ChemoendocrinetherapyRadiationtherapyAbemaciclibTDM-1(Ado-trastuzumabemtansine)2yearsTaxanesPertuzumabVenlafaxineEverymonthTamoxifenExemestaneLoperamideprophylaxis1yearCapecitabine10yearsOlaparibAnthracyclinesLVEFmonitoringAromataseinhibitorsPercentageneeded to beconsidered HR+(adjuvantendocrine therapyconsidered)PembrolizumabTC (docetaxel /cyclophosphamide)Intermediate(11-25)TNBCChemoendocrinetherapyRadiationtherapyAbemaciclibTDM-1(Ado-trastuzumabemtansine)2yearsTaxanesPertuzumabVenlafaxineEverymonthTamoxifenExemestaneLoperamideprophylaxis1yearCapecitabine10yearsOlaparibAnthracyclinesLVEFmonitoringAromataseinhibitorsPercentageneeded to beconsidered HR+(adjuvantendocrine therapyconsidered)PembrolizumabTC (docetaxel /cyclophosphamide)Intermediate(11-25)TNBC

Early-Stage Breast Cancer - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
  1. Chemoendocrine therapy
  2. Radiation therapy
  3. Abemaciclib
  4. TDM-1 (Ado-trastuzumab emtansine)
  5. 2 years
  6. Taxanes
  7. Pertuzumab
  8. Venlafaxine
  9. Every month
  10. Tamoxifen
  11. Exemestane
  12. Loperamide prophylaxis
  13. 1 year
  14. Capecitabine
  15. 10 years
  16. Olaparib
  17. Anthracyclines
  18. LVEF monitoring
  19. Aromatase inhibitors
  20. Percentage needed to be considered HR+ (adjuvant endocrine therapy considered)
  21. Pembrolizumab
  22. TC (docetaxel / cyclophosphamide)
  23. Intermediate (11-25)
  24. TNBC